CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China
The facility will be designed and constructed based on global cGMP requirements and is expected to have capacity for large scale production. The facility will be a key asset supporting CASI's growth and commercialization plans with further agreements to be finalized and site construction to begin in mid-2019.
About
Forward Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including: risks relating to interests of our largest stockholders that differ from our other stockholders; the difficulty of executing our business strategy in
EVOMELA®, Marqibo® and Zevalin® are proprietary to Spectrum Pharmaceuticals, Inc. and its affiliates.
CONTACT: |
INVESTOR CONTACT:
|
MEDIA CONTACT: |
View original content to download multimedia:http://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-build-gmp-manufacturing-site-in-wuxi-china-300751946.html
SOURCE
Los Angeles man who allegedly drove 2 autistic children to their deaths to collect insurance money is behind bars
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News